Chunlab launches new microbiome healthcare solution

Shim Hyun-tai  Published 2020.06.30  17:03  Updated 2020.06.30 17:03


Chunlab, a company specializing in the microbiome, launched a three-step program of microbiome healthcare, in a news conference at Plant Hall in southern Seoul on Tuesday.

Microbiomes are micro-organisms – living things too small to be seen – that exist in a particular environment or the human body.

The first step is "Gut Inside" microbiome examination or questions to confirm the intestinal type; the second step is the provision of customized pro- and prebiotics "Chunlab Biotics": and the third step is the management through the Pibio application.

The company has provided its analysis platform, "EzBioCloud," which is used by more than 37,000 people in 150 countries, as a solution for microbiome researchers. The personalized program presented on Tuesday will provide services to general consumers. The service can help individuals manage their health by balancing the intestinal microbiome ecosystem.

Chunlab CEO Chun Jong-sik explains new three-step microbiome service, during a news conference Tuesday.

Chunlab has established human microbiome big data for each disease and developed gut microbiome index (GMI), an intestinal microbiome health index, through several in-house studies, including clinical research and two civil science projects with large medical institutions.

GMI reflects the diversity of microorganisms, the proportion of microorganisms that cause inflammation or produce inflammatory inhibitors, and intestinal similarity with hunter-gatherers. It can comprehensively evaluate the intestinal microbiome environment.

The first step is to find the person's GMI index and intestinal-type through Gut Inside service or survey to confirm the type of bowel. Gut Inside analyzes microbial genes in feces and provides solutions to predict the risk and prevent the 25 diseases related to the microbiome.

The second step provides ChunLab Biotics, a customized pro- and prebiotic for each intestine type, according to the results of the first step. The company carefully selected strains that effectively respond to the intestinal microbial ecosystem depending on the type of the gut and divided into P, B, and O.

The third and final step is to use the Pibio application, which monitors the trend of microbiome changes by continuously recording answers to questions that predict the microbiome's status in the gut.

"Our healthcare service will provide a momentum to transform the paradigm of existing health care methods," Chunlab CEO Chun Jong-sik said. "We have developed an integrated solution to manage microbiome throughout people's life cycle based on our microbiome-based platform's accumulated technology."

<© KBR , All rights reserved.>